New biotech ven­ture fund de­buts with $300M for a mix of US and Eu­ro­pean play­ers

There’s an­oth­er new biotech ven­ture fund in play. And this one is launch­ing with an ex­pe­ri­enced ven­ture play­er at the helm and a clear mis­sion to put its mon­ey in­to US and Eu­ro­pean star­tups look­ing to break new ground in drug de­vel­op­ment.

Wel­come Piv­otal bioVen­ture Part­ners and Man­ag­ing Di­rec­tor Tra­cy Sax­ton. Sax­ton is a vet of both Roche Ven­ture Fund as well as SV Life Sci­ences Ad­vis­ers. And now she’s build­ing a team of six to eight who will be charged with in­vest­ing $300 mil­lion com­ing from Vin­cent Che­ung and the Hong Kong-based Nan Fung Group, an in­flu­en­tial con­glom­er­ate which has been spread­ing its wings be­yond big re­al es­tate projects in­to the biotech world.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.